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Abstract The mechanism(s) by which the E4 isoform of
apolipoprotein E (apoE4) influences Alzheimer’s disease (AD)
are not fully known. We report that apoE4, but not apoE3,
disrupts carbachol-stimulated phosphoinositide (PI) hydrolysis in
SH-SY5Y neuroblastoma cells. Carbachol responses were also
disrupted by L-amyloid (AL) (1^42) and apoE4/AL(1^42)
complexes, but not by apoE3/AL(1^42). Glutathione and
estrogen protected against apoE4 and AL(1^42) effects, as well
as those of H2O2. Estrogen protection was partially blocked by
wortmannin, suggesting the involvement of phosphatidylinositol
3-kinase. An apoE4-induced disruption of acetylcholine muscari-
nic receptor-mediated signalling may explain the lower effec-
tiveness of cholinergic replacement treatments in apoE4 AD
patients. Also, the beneficial effect of estrogen in AD may be
partially due to its ability to protect against apoE4- and AL(1^
42)-mediated disruption of PI hydrolysis. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
A wealth of genetic, histological and biochemical evidence
has implicated apolipoprotein E (apoE) in the pathogenesis of
Alzheimer’s disease (AD). Of the three di¡erent apoE iso-
forms (E2, E3 and E4), the dose of apoE4 both increases
the risk and reduces the age of onset for familial and sporadic
AD. A number of hypotheses have been proposed to explain
the isoform-speci¢c association of apoE and AD. ApoE iso-
forms may contribute di¡erentially to the disease through iso-
form-speci¢c interactions with L-amyloid (AL), the major
component of plaques. ApoE isoforms may also di¡erentially
bind and sequester the tau protein component of neuro¢bril-
lary tangles to prevent its phosphorylation (for review, see
[1]). Accumulating data support the possibility that apoE
may also directly in£uence intracellular signalling cascades.
ApoE has been shown to increase intracellular free Ca2 in
rat hippocampal astrocytes and neurons [2], and apoE4 has
been found to modulate activation of cAMP response ele-
ment-binding protein through the extracellular signal-regu-
lated kinase cascade [3]. We recently reported that apoE
and apoE/AL complexes can also induce protein kinase C-K
translocation in human neuroblastoma cells and ¢broblasts
[4].
The neurochemical pathology of AD includes the impair-
ment of a number of signal transduction pathways, including
those mediated by acetylcholine. Acetylcholine muscarinic ag-
onist stimulation of phosphoinositide (PI) hydrolysis is re-
ported to be approximately 50% lower in the prefrontal cortex
of AD brains as compared to controls [5]. Also, Ladner and
colleagues reported a disruption of muscarinic M1 receptor^
G-protein coupling in AD brain regions showing extensive
senile plaque accumulation [6].
It has also been shown that there is an association between
inheritance of apoE4 and the extent of cholinergic dysfunction
in AD. ApoE4 carriers with AD show a greater de¢cit in
cholinesterase activity in the hippocampus and cortex [7,8].
Also, the total number of cholinergic neurons is more severely
reduced in apoE4 AD subjects [7]. Although muscarinic re-
ceptor levels do not di¡er signi¢cantly between AD patients
with di¡erent apoE genotypes, apoE4 carriers are reported to
have poorer responses to acetylcholinesterase inhibitor thera-
pies, as compared to non-apoE4 subjects [8].
Increasing evidence indicates that oxidative stress also plays
an important role in AD pathogenesis (for review, see [9]),
and indeed may contribute to the cholinergic disruption seen
in the disorder, as well as to the mechanism of action of apoE.
AL has been shown to disrupt agonist-induced muscarinic
cholinergic signal transduction by a free radical-mediated
mechanism [10]. Miyata and Smith [11] reported a di¡erential
antioxidant ability of apoE isoforms to protect against AL-
and H2O2-induced oxidative stress. Recently, Pedersen et al.
[12] reported that apoE also has an isoform-speci¢c capability
of protecting against lipid peroxidation by isoform-speci¢c
binding to 4-hydroxynonenal (HNE), one of its toxic prod-
ucts. In both reports, the di¡erent apoE isoforms were seen to
be protective with the rank order of E2sE3sE4. These in
vitro ¢ndings are in agreement with AD post-mortem brain
studies in which protein modi¢cation by HNE [13] and higher
oxidative insults [14] are associated with inheritance of the
apoE4 allele.
The present study tests the hypothesis that apoE isoforms
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exert di¡erential e¡ects on acetylcholine muscarinic receptor-
mediated signal transduction as a possible consequence of
increased oxidative stress. To this end we investigated the
e¡ects of variant apoE isoforms on basal and carbachol-
stimulated PI hydrolysis in human SH-SY5Y neuroblastoma
cells. We also determined the e¡ects of apoE isoforms in com-
plex with AL(1^42) as well as AL(1^42) alone. Finally, the
ability of several antioxidants (AO) to protect against the
potential e¡ects of apoE and AL(1^42) was studied.
2. Materials and methods
2.1. Materials
Chemicals and isotopes were purchased from the following compa-
nies: myo-[2-3H]inositol (10 Ci/mmol) from NEN Du Pont Europe;
carbamylcholine chloride (carbachol), glutathione (reduced form)
(GSH), 17L-estradiol (estrogen), vitamin E (K-tocopherol), n-propyl
gallate (3,4,5-trihydroxybenzoic acid n-propyl ester) (PG) and Dowex
1X8-200 (chloride form) were from Sigma-Aldrich, Sweden; AL(1^42)
was purchased from U.S. Peptide (CA, USA). Apolipoprotein E3 and
E4 isoforms were from Panvera (Madison, WI, USA).
All other chemicals were standard laboratory reagents.
2.2. Cell culture
Human SH-SY5Y neuroblastoma cells were cultured at 37‡C, 5%
CO2, in minimum essential medium (MEM) with Earle’s salts con-
taining 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin,
100 Wg/ml streptomycin (Gibco-BRL Life Technologies, European
Division).
2.3. Treatments
Treatments with apoE, AL(1^42) and apoE/AL(1^42) complexes
were done as described in previous studies [4,15]. In brief, AL(1^42)
was dissolved in serum-free MEM (pH 7.4) at a concentration of 10
WM and ‘aged’ for 72 h by incubation at 37‡C. Human recombinant
apoE isoforms were dissolved in serum-free MEM to a concentration
of 10 nM. The apoE/AL complexes were made by co-incubation at
37‡C in neutral pH for 24 h. A concentration of 10 nM apoE (E3 or
E4 isoform) was added to 48 h ‘aged’ 10 WM AL(1^42), mixed and
incubated together for 24 h at 37‡C.
GSH (325 WM), vitamin E (50 Wg/ml), and PG (50 WM) were dis-
solved in serum-free media. Estrogen and wortmannin were ¢rst dis-
solved in dimethyl sulfoxide (DMSO) and then in serum-free medium
to 10 WM and 100 nM concentrations, respectively. The ¢nal DMSO
dilution in the medium was 1:104 (v/v). An alternative control group
of cells treated with this DMSO concentration was included in the
experiments with estrogen and wortmannin.
2.4. PI hydrolysis assay
Cells were cultured until con£uence. One day prior to the experi-
ment, cells were changed to serum-free medium containing 5 WCi/ml
myo-[2-3H]inositol and incubated for 19 h. The medium was then
replaced with that for the di¡erent conditions plus 5 WCi/ml myo-
[2-3H]inositol. Cells were incubated in the presence of all treatments
for 5 h.
PI hydrolysis was measured essentially as described by Fowler et al.
[16]. After treatment, cells were harvested by scraping with a rubber
policeman in 4 ml phosphate-bu¡ered saline (PBS). Contents were
centrifuged at 1500 rpm for 15 min. Pellets were washed twice with
37‡C PBS and re-suspended in 3 ml 37‡C Krebs^Henseleit bicarbon-
ate bu¡er containing 10 mM LiCl (KHB/Li), gassed with 5% CO2/
95% O2 and centrifuged again (15 000 rpm, 15 min). Cell pellets were
re-suspended in 210 Wl KHB/Li, regassed and 50 Wl added to glass
centrifuge tubes containing 250 Wl KHB/Li bu¡er with or without 100
WM carbachol. The tubes were incubated at 37‡C under an atmos-
phere of 5% CO2/95% O2 with gentle agitation for 25 min. Incuba-
tions were stopped by adding 940 Wl of chloroform:methanol (1:2).
Tubes were incubated on ice for 30 min and phases separated by
adding 310 Wl chloroform and 310 Wl water followed by vortexing
and centrifugation. 750 Wl of the aqueous phase was removed and
labelled inositol phosphates (IPs) separated from myo-[3H]inositol
by Dowex chromatography. The chloroform phase was extracted
with 75 Wl HCl and tubes were vortexed again for 20 s, followed by
5 min centrifugation. The chloroform phase was removed, placed into
scintillation vials and allowed to evaporate before determination of
‘lipid dpm’ by scintillation spectroscopy. Results are expressed as dpm
IPs/(dpm IPs+dpm lipid). This unit is independent of the number of
cells aliquoted in each tube and of the degree of labelling of inositol
phospholipids [16].
2.5. Statistical analyses
Analyses of di¡erences were carried out by ANOVA followed by
Fisher’s PLSD post-hoc test. A value of P6 0.05 was considered sta-
tistically signi¢cant.
3. Results
3.1. E¡ects of apoE3, apoE4, AL(1^42) and apoE/AL
complexes on PI hydrolysis
Carbachol (100 WM) induced an approximate 2.5-fold ele-
vation in the cytosolic accumulation of IPs in SH-SY5Y neu-
roblastoma cells (Fig. 1A). Five hour treatment with 10 nM
apoE3 had no e¡ect on either basal or carbachol-stimulated
PI hydrolysis. In contrast, 5 h treatment with 10 nM apoE4
signi¢cantly reduced the carbachol-stimulated accumulation
of IPs, with no e¡ect on basal responses (Fig. 1A). Carba-
chol-stimulated PI hydrolysis responses were also reduced by
10 WM AL(1^42). Complexes of apoE4/AL signi¢cantly re-
duced both basal and carbachol-stimulated PI hydrolysis,
whereas apoE3/AL complexes were without e¡ect (Fig. 1A,B).
Fig. 1. E¡ects of 10 WM AL(1^42), 10 nM apoE3, 10 nM apoE4,
apoE3/AL(1^42), and apoE4/AL(1^42) complexes on basal and car-
bachol (100 WM)-stimulated PI hydrolysis in SH-SY5Y neuroblasto-
ma cells. Cells were treated for 5 h. Histograms show mean
þ S.E.M. of at least ¢ve independent experiments. A: Basal and car-
bachol-stimulated PI hydrolysis. B: The di¡erences (carbachol-
stimulated minus basal). Statistical analysis of the results was car-
ried out using ANOVA followed by Fisher’s post-hoc test.
**P6 0.01, ***P6 0.001 compared to controls (untreated cells).
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3.2. Estrogen and glutathione protect against AL(1^42)- and
apoE4-mediated disruption of PI hydrolysis
To determine whether the e¡ects of AL(1^42) and apoE4 on
PI hydrolysis were likely due to induction of oxidative stress,
we used a number of AO compounds in co-treatment with
either 10 WM AL or 10 nM apoE4 for 5 h. Neither vitamin
E (50 Wg/ml) nor PG (50 WM) was able to reverse the delete-
rious e¡ects of either AL(1^42) or apoE4 on carbachol-stimu-
lated PI hydrolysis (data not shown). In contrast, both 10 WM
estrogen and 325 WM GSH gave protection against the dis-
ruptive e¡ects of AL(1^42) (Fig. 2A) and apoE4 (Fig. 2B). No
e¡ects were found in cells treated with either estrogen or GSH
alone (data not shown). DMSO (1:104, v/v) had no e¡ect on
basal or carbachol-stimulated PI hydrolysis (data not shown).
We then tested whether the protective e¡ects of estrogen
were likely due to its antioxidant properties. For this we
used the oxidative agent H2O2, which has been shown to
inhibit carbachol-stimulated PI hydrolysis in SH-SY5Y neuro-
blastoma cells [17]. Five hour treatment with 1 mM H2O2
signi¢cantly reduced the response to carbachol with no e¡ect
on basal IP levels. A higher concentration of H2O2 (10 mM)
reduced both basal and carbachol-stimulated PI hydrolysis
(Fig. 3).
GSH (325 WM) gave protection against the H2O2 (1 mM)-
mediated disruption of PI hydrolysis, but not against that
induced by 10 mM H2O2 (Fig. 3). Estrogen (10 WM) protected
against the disruption of carbachol-stimulated PI hydrolysis
induced by 1 mM H2O2 and also partially that caused by 10
mM H2O2 (Fig. 3).
Since it has been reported that activation of phosphatidyl-
inositol 3-kinase (PI3K) mediates the neuroprotective e¡ect of
estrogen against glutamate-induced neurotoxicity [18], we also
Fig. 2. Estrogen (10 WM) and glutathione (GSH) (325 WM) protect
against the disruption of carbachol-stimulated PI hydrolysis due to
AL(1^42) (10 WM) (A) and apoE4 (10 nM) (B). Histograms repre-
sent means þ S.E.M. of three independent experiments with data of
basal and carbachol-stimulated PI hydrolysis. Signi¢cances were de-
termined using ANOVA followed by Fisher’s post-hoc test.
*P6 0.05, ***P6 0.001.
Fig. 3. Estrogen (10 WM) and glutathione (GSH) (325 WM) e¡ects
on H2O2-mediated disruption of PI hydrolysis. Histograms represent
means þ S.E.M. of three independent experiments with data of basal
and carbachol-stimulated PI hydrolysis. Signi¢cances were deter-
mined using ANOVA followed by Fisher’s post-hoc test. *P6 0.05,
**P6 0.01, ***P6 0.001.
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Fig. 4. Wortmannin (100 nM) blocks the protective e¡ects of estro-
gen (10 WM) against the disruption of carbachol-stimulated PI hy-
drolysis caused by AL(1^42) (10 WM) (A) and apoE4 (10 nM) (B).
Histograms represent means þ S.E.M. of three independent experi-
ments with data of basal and carbachol-stimulated PI hydrolysis ex-
pressed. Signi¢cances were determined using ANOVA followed by
Fisher’s post-hoc test. *P6 0.05, ***P6 0.001.
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performed experiments with the PI3K inhibitor wortmannin
(100 nM) to determine whether a similar mechanism mediated
the protective e¡ect of estrogen in our paradigm. As shown in
Fig. 4, treatment of SH-SY5Y cells with wortmannin alone
decreased basal, but had no e¡ect on carbachol-stimulated PI
hydrolysis. Data from cells treated with the combination of 10
WM estrogen, 100 nM wortmannin and either 10 nM apoE4 or
10 WM AL(1^42) showed that basal PI hydrolysis was signi¢-
cantly decreased, whereas the protective e¡ect of estrogen on
apoE4- or AL(1^42)-induced disruption of carbachol-stimu-
lated PI hydrolysis was partially reversed by wortmannin
(Fig. 4A,B).
4. Discussion
The association of apoE4 with sporadic and familial AD is
well demonstrated, although the mechanism(s) by which
apoE4 in£uences the pathology and onset of disease are not
fully understood. In the complexity of the AD scenario, both
cholinergic impairment and increased oxidative stress are be-
lieved to play important roles. Muscarinic agonist stimulation
of PI hydrolysis is impaired in AD brain, and can also be
disrupted by AL in vitro. The present study addresses the issue
of whether variant apoE isoforms di¡erently in£uence acetyl-
choline muscarinic receptor-mediated signalling.
We ¢rst demonstrated that a physiological concentration
(10 nM) of apoE4 could disrupt carbachol-induced PI hydro-
lysis in human SH-SY5Y neuroblastoma cells. In contrast,
apoE3 was without e¡ect, indicating selectivity for the patho-
genic E4 variant of the protein.
Independent studies have shown that presynaptic choliner-
gic markers, such as choline acetyltransferase activity and im-
munoreactivity, as well as levels of nicotinic and nerve growth
factor receptors are reduced to a greater extent in apoE4 AD
patients, as compared to non-apoE4 individuals [7,8]. The
association between cholinergic dysfunction and apoE4 was
also found to have an impact on responses to therapies based
on the enhancement of cholinergic neurotransmission [8]. An
impaired lipid delivery to the cholinergic system in apoE4
carriers has been proposed as one mechanism for this associ-
ation [7]. Our data indicate that the apoE4 isoform may also
have a direct negative e¡ect on cholinergic signalling.
To further investigate these e¡ects in the context of AD, we
studied the e¡ects of both apoE isoforms on the AL(1^42)-
induced disruption of PI hydrolysis. AL has been previously
found to decrease carbachol-stimulated signalling in cultured
rat cortical neurons [10]. In agreement with this, we found
that 10 WM AL(1^42) signi¢cantly decreased the responses
to carbachol in human SH-SY5Y neuroblastoma cells. No
e¡ect was seen when AL(1^42) was in complex with apoE3
(10 nM), suggesting that apoE3 may exert some protective
mechanism against the AL(1^42)-mediated disruption of PI
hydrolysis. In contrast, apoE4/AL(1^42) complexes decreased
both basal and carbachol-stimulated PI hydrolysis in SH-
SY5Y cells, suggesting some synergy of their respective e¡ects.
We also hypothesized that the di¡erent ability of variant
apoE isoforms to disrupt carbachol-stimulated PI hydrolysis
could be due to di¡erential abilities to induce oxidative stress.
Oxidative agents have been shown to inhibit acetylcholine
receptor-stimulated phosphoinositide signalling and even to
reduce the G-protein sensitivity of muscarinic receptors in a
number of in vitro models (for review see [19]), including in
SH-SY5Y neuroblastoma cells [17]. Another line of investiga-
tion proposes that the mechanism of apoE isoform association
with AD involves a di¡erential involvement of variant apoE
isoforms on neurotoxicity [20]. Post-mortem studies have
shown that protein modi¢cation by HNE [13] and higher oxi-
dative insults [14] in AD are associated with inheritance of the
apoE4 allele. ApoE4 has also been shown to be more sensitive
to oxidation than E3 [21]. On the other hand, apoE3 has been
shown to have a better antioxidant ability than E4 [11,12]. In
view of this, it is reasonable to suggest that a di¡erent involve-
ment of oxidative stress could explain the di¡erential e¡ects of
apoE isoforms on PI hydrolysis. In this context, apoE3 would
be expected to protect against the e¡ects of AL(1^42) due to
its reported antioxidant properties.
To determine if oxidative stress could mediate the apoE4-
and AL(1^42)-induced disruption of carbachol-stimulated PI
hydrolysis, we tested the ability of a number of compounds
with known AO properties to protect against these insults. We
found that GSH and estrogen were e¡ective, whereas neither
vitamin E, an inhibitor of lipid peroxidation, nor PG, an
inhibitor of lipid peroxidation and of superoxide radical-in-
duced oxidation, showed any protective e¡ect. Others have
shown that pretreatment (16 h) of cortical neurons with vita-
min E or PG can prevent AL(25^35)-induced impairment of
carbachol-stimulated calcium responses in rat cortical neurons
[10]. We chose not to pretreat cells with AO so as to avoid
potential e¡ects on the incorporation of myo-[2-3H]inositol
that could complicate comparison of the PI hydrolysis data.
The fact that GSH, an important intracellular AO against a
variety of oxidative species, protected completely against
AL(1^42) and partially against apoE4 disruptions of carba-
chol-stimulated PI hydrolysis demonstrates that oxidative
stress is involved in the e¡ects of those two molecules. Both
GSH and estrogen can protect human ¢broblasts against the
disruptive e¡ects of AL(1^42) and apoE4 on bradykinin-
stimulated PI hydrolysis (data not shown), suggesting that
e¡ects may be consistent between di¡erent cell types.
The potent protective e¡ect of estrogen against the detri-
mental e¡ects of apoE4 and AL(1^42) on PI hydrolysis is in
contrast to the fact that only GSH (used at a super-physio-
logical concentration of 325 WM) and not the other classical
AOs vitamin E and PG showed protection. This ¢nding could
have particular importance since estrogen replacement ther-
apy in postmenopausal women is associated with a reduced
risk for AD (for review, see [22]), and also enhances the re-
sponses to acetylcholinesterase inhibitor treatments in women
with AD [23]. Estrogen is a multifaceted hormone that has
many cellular e¡ects, including interaction with second mes-
senger cascades and neuroprotection. We investigated if the
potent protective e¡ect of estrogen could be mediated by
mechanisms other than its AO properties. The AO e¡ects of
estrogen are generally seen with WM concentrations, while
other neuroprotective e¡ects are often found with signi¢cantly
lower concentrations (for review, see [22]).
The possibility that PI3K could mediate the protective ef-
fects of estrogen was tested using the speci¢c inhibitor wort-
mannin. In PI metabolism, phosphatidylinositol 4,5-bisphos-
phate (PIP2) is a substrate for both phospholipase C (PLC)
and PI3K. PI3K phosphorylates PIP2 to phosphatidylinositol
3,4,5-trisphosphate (PIP3), whereas PLC hydrolyzes this lipid
to produce diacylglycerol and IP3. Molecular cloning has re-
vealed three major families of PLC, L, Q and N (for review, see
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[24]). Estrogen has also been shown to use PLC-L to increase
intracellular calcium concentrations via rapid IP3 formation
[25]. Recent works have demonstrated cross-talk between both
signalling pathways. The PI3K product, PIP3, binds to PLC-Q
and enhances its activity [26]. In addition, PLC-Q can be regu-
lated by tyrosine protein kinases that also activate PI3K (for
review, see [24]). It has also been reported that tyrosine kinase
inhibitors can block the rapid generation of IP3 induced by
estrogen in a human hepatoma cell line [27]. Furthermore,
activation of PI3K mediates the neuroprotective e¡ect of es-
trogen against glutamate-induced neurotoxicity in cultured
cortical neurons [18]. We found that wortmannin blocked
the protective e¡ect of estrogen against both apoE4- and
AL(1^42)-induced disruption of carbachol-stimulated PI hy-
drolysis. This demonstrates that estrogen protection is medi-
ated at least in part by activation of PI3K. The decrease in
basal PI hydrolysis after wortmannin treatment is also consis-
tent with the inhibition of PLC-Q-mediated production of IPs.
In summary, the present report shows that apoE has iso-
form-speci¢c e¡ects on acetylcholine muscarinic receptor-
stimulated PI hydrolysis. We show that apoE4 impairs this
signalling pathway, while apoE3 alone is without e¡ect and
may indeed have a protective e¡ect against AL(1^42)-medi-
ated disruption. We also show that estrogen prevents the
apoE4- and AL(1^42)-induced impairment by a mechanism
which likely involves its AO e¡ect as well as PI3K activation.
This is to our knowledge the ¢rst study showing that apoE
has isoform-speci¢c e¡ects on acetylcholine muscarinic signal
transduction. Although we are aware of the limitations of an
in vitro model, our ¢ndings may help to explain the lower
e¡ectiveness of cholinergic replacement therapies in apoE4
AD patients. This study also provides new insight into the
mechanism of action of estrogen.
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